Aug 1 |
Eli Lilly CEO says weight loss drug shortage is ending
|
Aug 1 |
Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows
|
Aug 1 |
Lilly obesity drug shows heart benefit in late-stage trial
|
Aug 1 |
Eli Lilly Finds Yet Another Condition for Zepbound to Treat. The Stock Is Up.
|
Aug 1 |
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
Aug 1 |
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
|
Aug 1 |
Eli Lilly stock rises as weight loss drug tirzepatide reduces heart failure risks in study
|
Aug 1 |
What You Need to Know Ahead of Eli Lilly Earnings
|
Aug 1 |
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
|
Aug 1 |
AbCellera and Lilly broadens antibody discovery partnership
|